

**2024** ACGME ANNUAL EDUCATIONAL CONFERENCE

## SES093: Review Committee for Nuclear Medicine Update

Lance Hall, MD – Review Committee Chair

Felicia Davis, MHA – Review Committee Executive Director





### **Conflict of Interest Disclosure**

Speaker(s): Lance Hall, MD Felicia Davis, MHA

### **Disclosure**

None of the speakers for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

©2024 ACGME




# **Topics for Today...**


- Next Accreditation System Observations
- Accreditation Data System (ADS)
- Program Requirement Changes
- Review Committee Discussions
- Review Committee Composition



# Nuclear Medicine 2022-2023

- 36 accredited programs
- 85/141 (60%) filled/approved resident positions





# **Nuclear Medicine 10-Year Stats**

Academic Year	# Programs	On Duty
2013-2014	47	111
2014-2015	43	93
2015-2016	43	84
2016-2017	42	78
2017-2018	42	76
2018-2019	40	79
2019-2020	38	81
2020-2021	37	75
2021-2022	37	76
2022-2023	36	78
2023-2024	36	85

### Nuclear Medicine 10-year Trend



2024 ACGME ANNUAL EDUCATIONAL CONFERENCE ©2024 ACGME



#ACGME2024



## **Top 3 Most Flagged Areas**

- 1. Resident Survey (19%)
- 2. Clinical Experience (14%)
- 3. Faculty Survey (8%)

11% of programs flagged for the Resident Survey are also flagged for Clinical Experience

/	
0	Ó
ACC	G M E

### Nuclear Medicine Next Accreditation System Review Summary

64% programs	Compliant, no feedback
9% programs	Minor concerns, feedback in the form of Areas for Improvement (AFIs)
27% programs	Concerns, feedback either as citations and/or AFIs

#ACGME2024





- Major clinical/administrative changes in your program
- Highlight changes implemented to address AFIs
- Highlight program plans to address Resident Survey deficiencies
- Effects/impact of COVID-19 or other major events

# ACGME

### Nuclear Medicine Case Logs – Clinical Experience

- All programs are required to use the ACGME Case Log System.
- Residents must enter *all* specified procedures performed during their residency education into the ACGME Case Log System *regardless of stated minimums*.
- Still seeing erroneous or omitted data entry.
- Incomplete data impedes the Review Committee's ability to set and modify realistic future benchmarks for the specialty.

### NUCLEAR MEDICINE : NATIONAL RESIDENT REPORT (Main Table) Reporting Period: Total Experience of Residents Completing Programs in 2022-2023 Residency Review Committee for Nuclear Medicine Report Date: September 18, 2023

[PART	1]	Number of Programs in the Nation:	24	Number of Residents in the Nation:	36
-------	----	-----------------------------------	----	------------------------------------	----


			Participate/Interpret				
		Natl Res AVE	Natl Res STD	Natl Res MIN	Natl Res MED	Natl Res MAX	
RRC Area	RRC Type						
Parenteral Therapy	Parenteral therapy	29.5	24.7	5	22	88	
Radioiodine Therapy	Benign - less than or equal to 33 mCi l-131	10.5	5.8	0	11	26	
	Benign - greater than 33 mCi I-131	0.8	2.2	0	0	9	
	Malignant - less than or equal to 33 mCi I-131	3.2	6.3	0	1	33	
	Malignant - greater than 33 mCi I-131	20.2	9.8	6	19	50	
	Total Radioiodine Therapy	34.6	11.4	12	33	62	
Cardiac Stress Test	Cardiac stress test	215.1	257.1	0	131	1,395	
Pediatric Procedures	Pediatric	115.8	53.7	0	106	264	
Non-Req Add'l Procs	PET/CT Oncologic/tumor	233.8	388.4	0	2	1,554	
	PET/CT Other	13.2	32.0	0	0	175	
	Intravascular Particulate	0.6	3.2	0	0	19	

### NUCLEAR MEDICINE : NATIONAL RESIDENT STATISTICS REPORT (Resident Benchmarks Table) Reporting Period: Total Experience of Residents Completing Programs in 2022-2023 Residency Review Committee for Nuclear Medicine Report Date: September 18, 2023

[PART 1] Nur	nber of Programs in the Nation: 24 Nur	iber of Resident	s in the Nation:	30		
			Pa	rticipate/Interpre	et	
			Re	sident Percentil	es	
		10	30	50	70	90
RRC Area	RRC Type					
Parenteral Therapy	Parenteral therapy	6	11	22	36	75
Radioiodine Therapy	Benign - less than or equal to 33 mCi I-131	4	7	11	13	19
	Benign - greater than 33 mCi I-131	0	0	0	0	4
	Malignant - less than or equal to 33 mCi I-131	0	0	1	3	8
	Malignant - greater than 33 mCi I-131	9	15	19	22	34
	Total Radioiodine Therapy	21	30	33	37	54
Cardiac Stress Test	Cardiac stress test	100	106	131	202	392
Pediatric Procedures	Pediatric	59	103	106	126	183
Non-Req Add'l Procs	PET/CT Oncologic/tumor	0	0	2	237	808
	PET/CT Other	0	0	0	10	50



- Many programs providing inadequate block diagrams
- Not representative of a three-year curriculum
- Nuclear medicine is a three-year specialty program; This should be reflected on the block diagram
  - Even programs with recruiting practices that only consider NM2 or NM3 residents



#ACGME2024



- Block diagram should be free of individual resident names or identifiers
- If abbreviations are used for rotations or site names, a key must be provided
- A block diagram guide is available on the Documents and Resources page of the Nuclear Medicine section of the ACGME website

## **Block Diagram Example**

### NM-1 (PGY-2) Rotation Block Diagram (13 x 4-week blocks)

Block	1	2	3	4	5	6	7	8	9	10	11	12	13
Site	1	2	1	2	3	1	2	2	1	1	2	2	1
Rotation	Radio-	General	General	General	Pediatric	General	General	CT	PET/C	General	Research	General	General
Name	pharmacy/	Nuc Med	Nuc Med	Nuc	Nuc Med	Nuc Med	Nuc		Т	Nuc Med		Nuc Med	Nuc Med
	Nuc Med			Med			Med						

NM-2 (PGY-3) Rotation Block Diagram (13 x 4-week blocks)

Block	1	2	3	4	5	6	7	8	9	10	11	12	13
Site	2	2	3	1	1	2	2	2	1	3	1	1	2
Rotation Name	СТ	General <u>Nuc</u> Med	Pediatric <u>Nuc</u> Med	PET/CT	General <u>Nuc</u> Med	Research	СТ	General <u>Nuc</u> Med	PET/C T	Pediatric <u>Nuc</u> Med	Elective	General <u>Nuc</u> Med	СТ

NM-3 (PGY-4) Rotation Block Diagram (13 x 4-week blocks)


Block	1	2	3	4	5	6	7	8	9	10	11	12	13
Site	1	1	1	2	2	2	1	1	2	3	2	1	2
Rotation Name	PET/CT	Radiation Oncology	MRI	General <u>Nuc</u> Med	Research	СТ	PET/CT	General <u>Nuc</u> Med	СТ	Pediatric <u>Nuc</u> Med	General <u>Nuc</u> Med	PET/CT	General Nuc Med

Sites: (1) University of XXXXXX (Primary), (2) XXXXXX VA Hospital, (3) XXXXXXX Children's Hospital Available Electives: (both at Site 1): Medical Oncology, Cardiology — most residents elect to do 2 weeks in each. Vacation: Scheduled by the resident with program director consent. No more than 2 weeks may be taken off during any 4-week block.

**#ACGME2024** 

### **Nuclear Medicine Year ADS Consideration**

Entering resident has:	Resident status in ADS
< 12 months of training remaining	= NM3 (or year in program 3)
Between 24 and 12 months of training remaining	= NM2 (or year in program 2)
Between 36 and 24 months of training remaining	= NM1 (or year in program 1)



#ACGME2024



### **Review Committee Discussions**



#ACGME2024



## **ABNM Proposal/Adjustment**

Nuclear M	ledicine PRs	AB*	onal Requ	irements
<ul> <li>30 oral adn</li> </ul>	nin of I-131	*	Current	Provisional
[(IV.C.7.d).(1).(a).(i)] • <b>10 malign</b>	ant cases	31 <33 mCi benign	10-15	5+
<ul> <li>10 benigr</li> </ul>	cases ast	I-131 >33 mCi malignant	10-15	5+
		Parenteral	5	10+*
• 5 cases ther	ceral	Total Therapies	35	35
ther		*At least 2 different FDA a excluding Y90 Microsphe		armaceuticals

IV.C.7.d).(1)	Patient Care
IV.C.7.d).(1).(a)	<u>D</u> eocumentation in the ACGME Case Log System of participation in the following required nuclear medicine therapeutic procedures:
IV.C.7.d).(1).(a).(i)	<u>a minimum of 35 therapeutic drug</u> <u>administrations, including the</u> -following <u>minimums in each therapy type as outlined</u> <u>below, excluding Y-90 microspheres;-</u>
liver tumors to be a form of m whereas other parenteral radii 10 CFR. 35.396. It is preferred that the residen Committee recognizes that Y	d and Intent: The NRC considers Y-90 microsphere ablation of anual brachytherapy, which is regulated under 10 CFR 35.1000, iopharmaceuticals are considered to be drugs, regulated under at experience include a variety of radioisotopes. The Review -90 microsphere therapy is an important part of this experience participate when they have the opportunity, in addition to the appeutic drug administrations.
IV.C.7.d).(1).(a).(ii)	a minimum of <u>1030</u> cases of oral administration of sodium iodide I-131, for which a written directive is required; <sup>(Core)</sup>
IV.C.7.d).(1).(a).(ii).(a)	At least <mark>10 <u>five</u> of these cases must be for malignant disease, and at least <u>five10</u> cases must be for benign disease. <sup>(Core)</sup></mark>
IV.C.7.d).(1).(a).(ii).(b)	At least three of these cases must be less than or equal to 1.22 gigabecquerels (33 millicuries) of

### Recent Nuclear Medicine Requirement Revision

sodium iodide I-131, and at least three cases must be greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131. (Core)

a minimum of <u>10 five</u>-cases of parenteral administration of any alpha emitter, beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV, for which a written directive is required, and/or parenteral administration of any other radionuclide, for which a written directive is required,; and, at least two different US Food and Drug Administration-approved radiopharmaceuticals; and, (Core) Recent Nuclear Medicine Requirement Revision

Specialty-Specific Background and Intent: It is preferred that the resident experience include a variety of radioisotopes.

IV.C.7.d).(1).(a).(iv)a minimum of 100 cardiovascular<br/>pharmacologic and/or exercise stress<br/>studies. (Core)IV.C.7.d).(1).(b)documentation, in the ACGME Case Log System,<br/>of participation in therapeutic procedures, including<br/>date, diagnosis, and administered activity of each<br/>therapy; (Core)

**#ACGME2024** 

IV.C.7.d).(1).(a).(iii)

#### #ACGME2024



### ABNM Programs and ABR 16-Month Pathway

- ABNM/ABR 16-month pathway:
  - ACGME-accredited nuclear medicine or nuclear radiology program required
  - Nuclear medicine program completed during fouryear diagnostic radiology program
  - Must complete nuclear medicine case experience requirements
  - Leads to dual certification eligibility from ABR in diagnostic radiology and ABNM in nuclear medicine

# **Nuclear Radiology Programs and ABR 16-month Pathway**

- ABR 16-month pathway:
  - ACGME-Accredited nuclear medicine or nuclear radiology program not required
  - Nuclear medicine program completed during fouryear diagnostic radiology program
  - Leads to dual certification eligibility by the ABR in diagnostic radiology and nuclear radiology
  - Not ABNM-eligible based on number of nuclear medicine rotations

# ACGME

## Nuclear Medicine Program Participation Tracking

- ADS question for all nuclear medicine programs to help the Review Committee track program participation.
  - Question: Does your program participate in diagnostic radiology training pathways that lead to ABNM and/or ABR nuclear radiology certification eligibility (i.e., 16 months of nuclear medicine in a four-year diagnostic radiology pathway)? Y/N
  - If yes, how many residents are participating this year?

### Currently -

- o 22/36 nuclear medicine programs participating
- o Total of 33 residents



### Nuclear Medicine/Nuclear Radiology Programs and ABR 12-month Pathway

- Likely that nuclear medicine programs will be asked to help facilitate
- Nuclear medicine programs may provide education/supervision resources for the pathway when applicable
- Nuclear medicine program efforts not formally recognized by the ACGME
- Participating residents not enrolled in nuclear medicine

ACGMF2024




### **Review Committee for Nuclear Medicine Composition**

- 3 nominating organizations ABNM, SNMMI, and AMA
- 8 voting members (includes one resident and one public member)
- 6-year terms, except for the resident member (2-year term)
- Program directors, chairs, faculty members
- Ex-officio from ABNM (non-voting)



### Review Committee for Nuclear Medicine Members 2023-2024

Delphine Chen, MD<br/>University of WashingtonJoyce Mhlanga, MBChB<br/>Washington University/B-JH/SLCH ConsortiumLance Hall, MD (Chair)<br/>Emory UniversityMiguel Hernandez Pampaloni, MD (Vice Chair)<br/>University of California, San FranciscoAndrei Iagaru, MD<br/>Stanford UniversityPeter Temsah, MD (Resident Member)<br/>St. Louis UniversityRuth Lim, MD<br/>Massachusetts General Hospital/Harvard Medical SchoolVacant (Public Member)<br/>Stanford University





## **Review Committee Staff**

Felicia Davis, MHA – *Executive Director* <u>fdavis@acgme.org</u>

Jenny Campbell, MA – Associate Executive Director jcampbell@acgme.org

Bianca Andino – *Accreditation Administrator* <u>bandino@acgme.org</u>





### ACGME Site Visits – Continued Accreditation Status

- The program 10-Year Accreditation Site Visit program has been discontinued.
- Program Self-Study currently paused, but will be reconfigured and no longer linked to a site visit.
- All related dates have been removed from all program profiles in ADS.
- Starting in 2024, the ACGME will conduct site visits annually for approximately one to two percent of programs on Continued Accreditation that have not had a site visit in approximately 10 years or more.
- These site visits will be identified through a sampling process and will support the ACGME's assurance responsibility to the public.
- All selected programs for 2024 were notified in January of the site visit target date (May-July 2024)

Questions can be directed to <u>accreditation@acgme.org</u>. <u>Site Visit FAQs</u> are located on the ACGME website. #ACGME2024




### The ACGME's Online Learning Portal

### Learn at ACGME Redesign Coming Soon!

Visit <u>dl.acgme.org</u> or scan the QR code.



Have a question or need assistance? Contact us! <u>desupport@acgme.org</u>







## **Remediation Toolkit**

### If You Build It, They Will Come:

**Designing a Centralized Remediation Program** 

Karen M. Warburton, MD, FACP, FASN Associate Professor of Medicine Director, Clinician Wellness Program Director, GME Advancement University of Virginia School of Medicine



- 11 modules authored by renowned experts in the field
- Equips participants with tools for addressing needs of struggling learners
- CME offered after completion






### **Applying for Program Accreditation Course**

Three-part course and step-by-step guide

For those new to the process, as well as a refresher for experienced users

Explanation of key steps, timeline, and the review process after submission








### Faculty Development Toolkit: Improving Assessment Using Direct Observation

- Faculty development materials around direct observation and feedback
- Evidence-based video prompts
- Answer keys and facilitator guides
- Microlearning lessons with associated slides and guides








## **Program Coordinator Course**

- For new and seasoned coordinators
- Covers a wide range of topics important to program coordinators
- Videos from working coordinators
- Summer 2024


ACGME



2024 ACGME ANNUAL EDUCATIONAL CONFERENCE ©2024 ACGME



# Questions?





# Thank You

©2024 ACGME